dorzagliatin

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

indie 13 5 月

14 minutes

SHANGHAI, CHINA, May 13, 2022 […]

Hua Medicine Announces 2021 Annual Results

indie 17 3 月

8 minutes

SHANGHAI, CHINA, Mar 17, 2022 […]

Hua Medicine Announces 2020 Interim Results

indie 19 8 月

7 minutes

SHANGHAI, CHINA, Aug 19, 2021 […]

Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine’s Dorzagliatin Readying for NDA Submission

indie 19 3 月

8 minutes

SHANGHAI, CHINA, Mar 19, 2021 […]

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

indie 18 12 月

12 minutes

SHANGHAI, CHINA, Dec 18, 2020 […]

Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin

indie 14 10 月

5 minutes

SHANGHAI, CHINA, Oct 14, 2020 […]

Copyright © 2020 ASEANPR.Com All rights reserved.